ODYSSEYRecruiting

Effects of Repeated Administration of Gadolinium-Based Contrast Media on Mobility and Cognitive Function

Gender
Women and men
Age
18–64 years
Trial type
Interventional
Line of therapy
all
Phase
Phase IV

What is this trial about?

are frequently used in imaging procedures such as to make organs and tissues more visible. The goal of the ODYSSEY study is to investigate whether repeated administration of gadolinium-based contrast agents over a five-year period affects motor function and cognitive function. Women and men between the ages of 18 and 64 who require regular imaging tests due to an existing medical condition and who are neurologically healthy are eligible to participate in this study.

Trial flow

Requirements

Diagnosis: Condition that requires MRI scans

Age: 18–64 years

Key inclusion criteria: Different conditions that require MRI

Allocation

Stratifizierung anhand von Markern

Treatment

Linear GBCAs prior to MRIGBCA, i.e. Eovist/ Primovist, MultiHance or Omniscan; study doctor visits at least 7 times for physical examinations, laboratory investigations and tests on body movement and mental skills within the 5 years
Macrocyclic GBCAs prior to MRIGBCA, i.e. Gadavist/ Gadovist, Dotarem, Magnescope or ProHance; study doctor visits at least 7 times for physical examinations, laboratory investigations and tests on body movement and mental skills within the 5 years
No GBCA prior to MRIStudy doctor visits at least 7 times for physical examinations, laboratory investigations and tests on body movement and mental skills within the 5 years

Follow-up

60 months

Detailed description

Magnetic resonance imaging (MRI) is an imaging technique that does not use X-rays and provides detailed images of the body’s interior. To better visualize certain structures, a is administered through a vein (intravenously) before the exam. Gadolinium-based contrast agents contain the metal , which may remain in the body in small amounts after administration. It is not yet conclusively clear whether these deposits have long-term health effects.

The goal of this Phase 4 study is to investigate, over a period of five years, whether repeated administration of contrast agents affects patients’ motor or cognitive abilities. Two types of gadolinium-based contrast agents will be compared: linear contrast agents, in which gadolinium is bound in a chain-like structure, and , in which gadolinium is enclosed in a ring-like structure and is therefore considered more stable. Patients are not randomly assigned but are placed in one of three based on the contrast agent already used in their clinical care: a study arm with linear contrast agents, a study arm with macrocyclic contrast agents, or a without contrast agent administration. Patients in the control arm must not have previously received any gadolinium-based contrast agent. Throughout the study period, an scan or other imaging tests (such as or X-ray) will be performed annually. In addition, assessments of motor function and cognitive performance will be conducted, along with blood and urine tests to measure gadolinium levels in the body. At the beginning and end of the study, all patients will undergo an MRI scan of the brain without contrast agent.

Eligible participants are patients between the ages of 18 and 64 who require imaging at least once a year due to an existing medical condition. These include, among others, breast cancer , prostate monitoring, chronic liver diseases, colorectal tumors, , and pancreatic cysts. Another requirement is that participants have no neurological or psychiatric conditions that could influence the test results.

Facts

  1. What condition: Various conditions requiring regular imaging (e.g., breast cancer , prostate monitoring, chronic liver diseases, colorectal tumors, , pancreatic cysts)
  2. Cancer characteristics: no requirements
  3. What the study investigates: the effect of repeated administration on motor and cognitive functions
  4. Study objective: to investigate the potential effects of deposits on mobility and cognitive function
  5. How long will the study last: 5 years
  6. Study characteristics: Phase 4 study, non-, open-label, three (linear, macrocyclic, without contrast agent)

Trial sites

2 trial sites in Germany are listed.

  • Vivantes - Netzwerk fuer Gesundheit GmbH

    Rudower Strasse 48, 12351 Berlin

    Recruiting
  • Universitätsklinikum Tübingen

    72076 Tübingen

    Active, not recruiting

This list is compiled to the best of our knowledge but without guarantee: it may be incomplete, and a site's recruitment status can change at any time. Last checked against the trial registers on .

Medical editorial team

  • Dr. med. Sebastian SommerSpecialist in internal medicine with a focus on hematology and oncology
  • PD Dr. med. Matthias FröhlichSpecialist in internal medicine, immunology and emergency medicine

This description is based on the public trial registry entry and was translated into plain language by our medical editorial team. Whether participation is an option for you is a decision you make together with your treating physician.